Short term safety of BNT162b2 (Pfizer–BioNTech) SARS-CoV-2 vaccine among children aged 5–11 years, a nationwide parental survey

Shirley Shapiro Ben David*, Sharon Baruch Gez, Limor Adler, Rada Kovatch, Daniella Rahamim-Cohen, Na'ama Shamir-Stein, Arnon Shahar, Miri Mizrhi-Reuveni

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose: SARS-CoV-2 vaccine safety is of major interest worldwide, and transparent information about potential side effects is essential to decrease vaccine hesitancy. The aim of this study was to assess SARS-CoV-2 BNT162b2 vaccine short-term side effects among children aged 5–11 years. Methods: An observational, cross sectional study of vaccine side-effects using electronic surveys sent to parents one week post administration of BNT162b2 vaccine to their child in a large health maintenance organization in Israel. Results: First dose and second dose surveys were filled for 5,842 and 6,126 children, respectively, with a response rate of 32.1% and 24.8%. Local side effects were reported by 68.7% and 69.1% of the first and second survey respondents, and general side effects were reported by 20.8% and 34.5% of them. The symptoms most frequently reported were fatigue, headache and myalgia. Duration of symptoms lasted three days or less among 86.5% and 81.5% of first and second dose survey respondents. Most respondents (92%) reported that their child did not need any medical consultation following vaccination. Conclusions: We found further support for the BNT162b2 SARS-CoV-2 vaccine short- term safety among children aged 5–11 years. With ongoing pandemic and future booster COVID-19 vaccines, these findings can encourage vaccine confidence for parents and providers.

Original languageEnglish
Pages (from-to)1154-1159
Number of pages6
Issue number5
StatePublished - 15 Feb 2024


  • BNT162b2 vaccine
  • COVID-19
  • Children
  • SARS-CoV-2
  • Safety
  • Side effects


Dive into the research topics of 'Short term safety of BNT162b2 (Pfizer–BioNTech) SARS-CoV-2 vaccine among children aged 5–11 years, a nationwide parental survey'. Together they form a unique fingerprint.

Cite this